PitchSend

Investor Presentaiton

ONENESS Upcoming 2022 and Beyond Milestones Fespixon (ON101) • Market entry into China (2022) Out-license in EU/US (2022) • Initiate rolling submission in the US (2022) FB825 • Ph2a Atopic Dermatitis completion (2022) • Ph2a Allergic Asthma completion (2023) FB704A Ph2a severe asthma (2023) • Evaluate to initiate Ph2a CKD-induced CVD (2022) SNS812 Initiate first-in-patient clinical trial (2022) | 33

View entire presentation